U.S. market Closed. Opens in 11 hours 43 minutes

PRLD | Prelude Therapeutics Incorporated Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/AN/A
Cost of Revenue1.17M3.04M2.24M542.00K382.00KN/A
Gross Profit-1.17M-3.04M-2.24M-542.00K-382.00KN/A
Operating Expenses131.11M123.54M113.73M58.76M28.11M14.97M
Selling, General & Admin27.71M30.65M26.96M10.59M3.83M2.35M
Research & Development103.39M92.89M86.78M48.18M24.28M12.62M
Other Operating ExpensesN/A8.10M2.04M1.83M539.00K295.00K
Operating Income-132.28M-123.54M-113.73M-58.76M-28.11M-14.97M
Other Expenses / Income10.44M8.10M2.04M1.83M539.00K295.00K
Before Tax Income-121.83M-115.44M-111.69M-56.93M-27.57M-14.68M
Income Tax Expenses-1.00-8.10M-915.00K335.70K210.14K295.00K
Net Income-121.83M-107.34M-110.78M-56.93M-27.57M-14.68M
Interest ExpensesN/A-1.32MN/AN/AN/AN/A
Basic Shares Outstanding60.36M47.37M47.60M43.71M32.40M32.11M
Diluted Shares Outstanding60.36M47.37M47.60M43.71M32.40M32.11M
EBITDA-131.11M-123.54M-113.73M-58.22M-27.73M-14.83M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-121.83M-116.76M-111.69M-56.59M-27.36M-14.38M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙